Indiplon
Indiplon[edit]
Indiplon is a nonbenzodiazepine hypnotic agent that was developed for the treatment of insomnia. It acts as a positive allosteric modulator of the GABA_A receptor, which is a type of neurotransmitter receptor in the central nervous system.
Mechanism of Action[edit]
Indiplon works by enhancing the effects of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA_A receptor. This receptor is a ligand-gated ion channel that, when activated, allows chloride ions to enter the neuron, leading to hyperpolarization and decreased neuronal excitability. By modulating this receptor, Indiplon increases the inhibitory effects of GABA, promoting sedation and sleep.
Pharmacokinetics[edit]
Indiplon is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1 to 2 hours. It is extensively metabolized in the liver by the cytochrome P450 enzyme system, primarily by CYP3A4. The metabolites are excreted in the urine. The half-life of Indiplon is approximately 1 to 2 hours, which makes it suitable for use as a sleep aid with minimal hangover effect the next day.
Clinical Use[edit]
Indiplon was developed to treat insomnia, particularly difficulties with sleep onset. It was designed to have a rapid onset of action and a short duration, making it effective for individuals who have trouble falling asleep but do not necessarily have issues with staying asleep.
Development and Approval[edit]
Indiplon was developed by Neurocrine Biosciences and was submitted for approval to the United States Food and Drug Administration (FDA). However, the FDA issued a non-approval letter, citing concerns about the drug's safety and efficacy profile. As a result, Indiplon was never marketed in the United States.
Side Effects[edit]
Common side effects of Indiplon include drowsiness, dizziness, and headache. Like other hypnotics, it may also cause amnesia, confusion, and impaired coordination. There is also a potential for dependence and withdrawal symptoms with prolonged use.
